Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome

Leukemia

Volumn 20, Issue 4, 2006, Pages 549-555

  Della Porta, M G ^a   Malcovati, L ^a   Invernizzi, R ^a   Travaglino, E ^a   Pascutto, C ^a   Maffioli, M ^a   Galli A ^a   Boggi, S ^a   Pietra, D ^a   Vanelli, L ^a   Marseglia, C ^a   Levi, S ^b   Arosio, P ^c   Lazzarino, M ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Erythroid dysplasia; Ferritin; Flow cytometry; Immunophenotyping; Myelodysplastic syndrome; Transferrin receptor

Indexed keywords

CD71 ANTIGEN; ENDOGLIN; FERRIC FERROCYANIDE; FERRITIN; TRANSFERRIN RECEPTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGEN EXPRESSION; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISCRIMINANT ANALYSIS; DISEASE SEVERITY; EDITORIAL; ERYTHROBLAST; ERYTHROID CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HEMATOPOIETIC STEM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; SIDEROBLASTIC ANEMIA;

EID: 33646480514     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404142     Document Type: Editorial

References (28)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005; 352: 536-538.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
3. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
4. Jacobs A. Myelodysplastic syndromes: Pathogenesis, functional abnormalities, and clinical implications. J Clin Pathol 1985; 38: 1201-1217.
5. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15-29.
6. Elghetany MT. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2002; 99: 391-392.
7. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ et al. Diagnostic utility of flow cytometric immuno phenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
8. Maynadié M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood 2002; 100: 2349-2356.
9. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.
10. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
11. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19: 776-783.
12. Invernizzi R, Cazzola M, De Fazio P, Rosti V, Ruggeri G, Arosio P. Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit. Br J Haematol 1990; 76: 427-432.
13. Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101: 1996-2000.
14. Buhring HJ, Muller CA, Letarte M, Gougos A, Saalmuller A, van Agthoven AJ et al. Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841-847.
15. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD. Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 1995; 154: 4456-4465.
16. Bernasconi P, Klersy C, Boni M, Cavigliano PM, Calatroni S, Giardini I et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: A study on 331 patients from a single institution. Leukemia 2005; 19: 1424-1431.
17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
18. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989; 52: 48-60.
19. Stelzer GT, Marti G, Hurley A, McCoy Jr P, Lovett EJ, Schwartz A. US-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standardization and validation of laboratory procedures. Cytometry 1997; 30: 214-230.
20. Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106: 247-253.
21. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516.
22. Levi S, Yewdall SJ, Harrison PM, Santambrogio P, Cozzi A, Rovida E et al. Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. Biochem J 1992; 288 (Part 2): 591-596.
23. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004; 119: 529-542.
24. Sanz C, Richard C, Prosper F, Fernandez-Luna JL. Nuclear factor k B is activated in myelodysplastic bone marrow cells. Haematologica 2002; 87: 1005-1006.
25. Campanella A, Isaya G, O'Neill HA, Santambrogio P, Cozzi A, Arosio P et al. The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet 2004; 13: 2279-2288.
26. Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 2005; 105: 2161-2167.
27. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004, 297-317.
28. Ramos F, Fernandez-Ferrero S, Suarez D, Barbon M, Rodriguez JA, Gil S et al. Myelodysplastic syndrome: A search for minimal diagnostic criteria. Leuk Res 1999; 23: 283-290.